Evidence map›Paper›PMID 30384333›Full record

ArticleTopics in antiviral medicine2018

Policy and advocacy for the HIV practitioner.

Carlos Del Rio, Wendy S Armstrong

Open access · greenAbstract read
In one paragraph

Article in Topics in antiviral medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Silence=Death Redux: Infectious Diseases, Public Health, and the Imperative to Resist.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Carlos Del RioEmory University School of Medicine, Atlanta, GA, USA.
Wendy S ArmstrongEmory University School of Medicine, Atlanta, GA, USA.
Emory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In no field of medicine has advocacy, including physician advocacy, been more crucial in shaping policy for delivery of care than in HIV/AIDS. Although the historic tradition is strong, there is an urgent need to re-energize advocacy efforts nationally and internationally to support programs that fund care, change policies that perpetuate stigma and discrimination, and change the public perception that the HIV/AIDS crisis is over. Established programs that require ongoing advocacy attention include the Ryan White Comprehensive AIDS Resources Emergency Act, a US program that serves as a payer of last resort for care for patients with HIV infection, and international programs like the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. Newer issues have emerged, including the need to ensure fair drug pricing and guarantee sustained access to care and medications. Amidst the opioid epidemic, the preservation and establishment of policies to support syringe services programs take on new urgency, and ongoing efforts are necessary to decrease stigma about HIV infection, maintain protection of LGBTQ rights, and reform HIV criminalization laws. All stakeholders in the HIV community, including practitioners, individuals with HIV infection, and professional organizations, need to make their voices heard as they have done in the past in order to effectively continue to address the epidemic. This commentary was submitted by Carlos del Rio, MD, and Wendy S. Armstrong, MD, in March, 2018, and accepted in July, 2018.

Indexed as

Consumer AdvocacyHealth PolicyGlobal HealthHIV InfectionsHumans

Identifiers

PMID30384333
PMCPMC6291296
OpenAlexW2990825584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.